INTRODUCTION {#s1}
============

Topoisomerase IIA (TOP2A) is an essential nuclear enzyme that cleaves and recombines double-stranded DNA in processes such as replication, transcription, condensation, and segregation \[[@R1]\]. TOP2A is expressed in proliferating cells in the late S and the G2-M phases, and TOP2A expression is known to be a prognostic factor in various malignancies \[[@R2]--[@R5]\]. In breast cancer, TOP2A protein or gene expression is also associated with a poor prognosis \[[@R6], [@R7]\]; the prognostic value is emphasized in hormone receptor-positive disease \[[@R8], [@R9]\]. Additionally, TOP2A is a molecular target of anthracycline, and previous reports have shown that *TOP2A* amplified or deleted are predictive markers of anthracycline-containing adjuvant chemotherapy regimens for early breast cancer \[[@R10]--[@R13]\].

Although TOP2A status has several important implications in breast cancer, the standard tools and cutoff values for estimating TOP2A status have not been established \[[@R14]\]. Additionally, previous reports of the predictive and prognostic value of TOP2A status were based on classical adjuvant chemotherapy regimens without taxane and HER2-targeting therapies, which differed from modern clinical practice. The clinical significance and best assessment of TOP2A status need to be re-evaluated under modern tailored therapy based on breast cancer subtype.

At our institution, both TOP2A overexpression and *TOP2A* amplified had been consecutively evaluated using immunohistochemistry (IHC) and fluorescence *in situ* hybridization (FISH) in patients with breast cancer between May 2005 and April 2015. During this period, adjuvant therapies, including taxane and HER2 targeting therapy, were administered based on breast cancer subtype and the risk for recurrence. We retrospectively evaluated the prognostic value of TOP2A status in these patients with non-metastatic breast cancer.

RESULTS {#s2}
=======

Patient characteristics and TOP2A status {#s2_1}
----------------------------------------

The median and mean of TOP2A expression were 11.3% and 18.4%, respectively. Histogram of continuous IHC proportion scores of TOP2A is shown in ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). The frequency of TOP2A overexpression was 55.8% (359/643). The numbers for *TOP2A* amplified, normal, and deleted were 61 (9.5%), 577 (89.7%), and 5 (0.8%), respectively. The associations of the clinicopathological factors with TOP2A overexpression and *TOP2A* amplified are shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, respectively. TOP2A overexpression showed a significant correlation with larger T stage (*p \<* 0.001), node positivity (*p \<* 0.001), high nuclear grade (*p \<* 0.001), ER negativity (*p \<* 0.001), PgR negativity (*p \<* 0.001), HER2 positivity (*p \<* 0.001), and high Ki67 index (*p \<* 0.001) using the χ^2^-test. TOP2A overexpression was recognized in non-luminal A subtype (rate of overexpression, luminal A vs. non-luminal A, 8.3% vs. 65.4%, χ^2^-test, *p \<* 0.001). Although the associations between *TOP2A* amplified and several clinicopathological factors, including larger T, high nuclear grade, and high Ki67 index, were significant, almost *TOP2A* amplified was observed in HER2 positive breast cancers; specifically, the rates of *TOP2A* amplified were 42.2% (57/135) and 0.8% (4/508) in HER2-positive and -negative cancers, respectively. Thus, the characteristics of *TOP2A* amplified breast cancer reflected those of HER2 positive breast cancer.

###### Clinicopathological factors and TOP2A overexpression

                                                 TOP2A overexpression                        
  ---------------------------- ----------- ----- ---------------------- ------ ------ ------ ---------
  age                          50≥         14    87                     61.7   54     38.3   0.11
  50\<                         502         272   54.2                   230    45.8          
  T                            ^\*^0       2     2                      100    0      0      \<0.001
  1                            366         163   44.5                   203    55.5          
  2                            211         143   32.2                   68     67.8          
  3                            36          26    72.2                   10     27.8          
  4                            28          25    89.3                   3      10.7          
  N                            0           422   211                    50     211    50     \<0.001
  1                            172         111   64.5                   61     35.5          
  2                            35          27    77.1                   8      22.9          
  3                            14          4     71.4                   10     28.6          
  Stage                        1           302   132                    43.7   170    56.3   \<0.001
  2                            262         166   63.4                   96     33.8          
  3                            79          61    77.2                   18     22.8          
  nuclear grade                1           291   83                     28.5   208    71.5   \<0.001
  2                            161         103   64                     58     36            
  3                            263.6       173   90.6                   18     9.4           
  ER                           positive    498   250                    50.2   248    49.8   \<0.001
  negative                     145         109   75.2                   36     24.8          
  PgR                          positive    434   218                    50.2   216    49.8   \<0.001
  negative                     209         141   67.5                   68     32.5          
  HER2                         positive    134   107                    79.3   27     20.7   \<0.001
  negative                     509         252   49.6                   257    50.4          
  Ki 67                        14%\>       211   23                     10.9   188    89.1   \<0.001
  ≧14%                         432         336   77.8                   96     22.2          
  subtype                      luminal A   108   9                      8.3    99     91.7   \<0.001
  luminal B                    315         179   56.8                   136    43.2          
  HER2                         135         107   79.3                   28     20.7          
  TNBC                         85          64    75.3                   21     24.7          
  TOP2A amplified              yes         61    48                     78.7   13     21.3   \<0.001
  no                           582         311   53.4                   271    46.6          
  Adjuvant chemotherapy        yes         309   235                    76.1   74     23.9   \<0.001
  no                           334         124   37.1                   210    62.9          
  Adjuvant radiation therapy   yes         413   232                    56.2   181    44.2   0.82
  no                           230         127   55.2                   103    44.8          
  recurrence                   yes         73    60                     82.2   13     17.8   \<0.001
  no                           570         299   52.5                   271    47.5          

*p* value was evaluated using χ^2^ test, ^\*^T0 means occult breast cancer.

Abbreviations: ER: estrogen receptor; PgR; progesteron receptor; HER2: human epidermal growth factor receptor 2 TNBC: triple negative breast cancer.

###### Clinicopathological factors and *TOP2A* amplified

                                                 *TOP2A* amplified                        
  ---------------------------- ----------- ----- ------------------- ------ ------ ------ ---------
  age                          50≥         14    17                  12.1   124    87.9   0.24
  50\<                         502         44    8.8                 458    90.2          
  T                            ^\*^0       2     0                   0      2      100    0.044
  1                            366         28    7.7                 338    92.3          
  2                            211         22    10.4                189    89.6          
  3                            36          4     11.1                32     88.9          
  4                            28          7     25                  21     75            
  N                            0           422   37                  8.8    385    91.2   0.052
  1                            172         15    8.7                 157    91.3          
  2                            35          8     22.9                27     77.1          
  3                            14          1     7.1                 13     92.9          
  Stage                        1           302   27                  8.9    275    91.1   0.073
  2                            262         21    8                   241    92            
  3                            79          13    16.5                66     83.5          
  nuclear grade                1           291   12                  4.1    279    95.9   \<0.001
  2                            161         19    11.8                142    88.2          
  3                            263.6       30    15.7                161    84.3          
  ER                           positive    498   41                  8.2    457    91.8   0.044
  negative                     145         20    13.8                125    86.2          
  PgR                          positive    434   39                  9      395    91     0.48
  negative                     209         22    10.5                187    89.5          
  HER2                         positive    134   57                  42.2   78     57.8   \<0.001
  negative                     509         4     0.8                 504    99.2          
  Ki 67                        14%\>       211   13                  6.2    198    93.8   0.044
  ≧14%                         432         48    10.9                384    89.1          
  subtype                      luminal A   108   0                   0      108    100    \<0.001
  luminal B                    315         1     0.3                 314    99.7          
  HER2                         135         57    42.2                78     57.8          
  TNBC                         85          3     3.5                 82     96.5          
  TOP2A overexpression         yes         359   48                  13.3   311    86.7   \<0.001
  no                           284         13    4.6                 271    95.4          
  Adjuvant chemotherapy        yes         309   48                  15.5   261    84.5   \<0.001
  no                           334         13    3.9                 321    96.1          
  Adjuvant radiation therapy   yes         413   41                  9.9    372    90.1   0.61
  no                           230         20    8.7                 210    91.3          
  recurrence                   yes         73    4                   5.5    69     94.5   0.21
  no                           570         57    10                  513    90            

*p* value was evaluated using χ^2^ test, ^\*^T0 means occult breast cancer.

Abbreviations: ER: estrogen receptor; PgR; progesteron receptor; HER2: human epidermal growth factor receptor 2 TNBC: triple negative breast cancer.

Prognostic value of TOP2A overexpression in each breast cancer subtype {#s2_2}
----------------------------------------------------------------------

In this study, the median follow-up period was 5.4 years. In the entire population, there was a significant association between TOP2A overexpression and relapse-free survival (5-year RFS; TOP2A overexpression vs. normal expression, 97.3% vs. 84.1%, *p \<* 0.001, log-rank test) (Figure [1A](#F1){ref-type="fig"}).

![Prognostic value of TOP2A overexpression in each breast cancer subtype\
Relapse-free survival of (**A**) all (*n* = 643), (**B**) luminal A (*n* = 108), (**C**) luminal B (*n* = 315), (**D**) HER2 (*n* = 135), and (**E**) TNBC (*n* = 85) subtypes stratified by TOP2A overexpression. *P* value was evaluated using the log-rank test. Abbreviations: HER2: human epidermal growth factor receptor 2; TNBC: triple negative breast cancer.](oncotarget-09-26701-g001){#F1}

In the subgroup analysis of breast cancer subtypes, TOP2A overexpression was a significant prognostic factor in luminal B breast cancer (5-year RFS; TOP2A overexpression vs. no overexpression, 98.5% vs. 81.3%, *p \<* 0.001, log-rank test); however, no such significant association was observed in other subtypes (Figure [1B--1E](#F1){ref-type="fig"}). In luminal B breast cancer, Cox regression analysis that included other prognostic factors, such as, age, T factor, N factor, nuclear grade, PgR positivity, and Ki67 index, showed that TOP2A overexpression was the strongest prognostic factor for RFS (hazard ratio \[HR\] 4.00, 95% confidence interval \[CI\] 1.65--9.54, *p \<* 0.001) (Table [3](#T3){ref-type="table"}). In an exploratory analysis, receiver operating characteristic (ROC) curve of SUVmax was drawn to determine the cutoff value that yielded optimal sensitivity and specificity for prediction of 5-year RFS in luminal B breast cancer based on the Youden index. The ROC curve indicated an optimal TOP2A expression cutoff value of 11.5% for predicting 5-year RFS (area under the curve, 0.74; 95% CI, 0.66--0.82; *P* \< .001; sensitivity, 87.9%; specificity, 59.6%). A continuous value of TOP2A expression was also shown to be the significant prognostic factor in luminal B breast cancer in Cox regression analysis (HR 1.07; 95% CI, 1.02--1.12, *P* = 0.005).

###### Multivariate Cox regression analysis of clinicopathological factors and TOP2A overexpression, with respect to relapse-free survival among patients with luminal B breast cancer (*n =* 315)

  factors                                 *n*                 hazard ratio (95% CI)   *p* value
  ---------------------------- ---------- ------------------- ----------------------- -----------
  age                          50≥        69                  1                       0.30
  50\<                         246        0.68 (0.34--1.36)                           
  T stage                      2 cm≥      177                 1                       0.036
  2 cm\<                       138        2.15 (1.05--4.39)                           
  Nodal status                 netative   202                 1                       0.012
  positive                     113        2.37 (1.21--4.62)                           
  PgR                          positive   249                 1                       0.57
  netative                     66         1.26 (0.57--2.78)                           
  nuclear grade                1, 2       236                 1                       0.85
  3                            79         1.1 (0.55--2.30)                            
  Ki67 (continuous value)                                     1.02 (1.00--1.04)       0.11
  adjuvant chemotherapy        no         183                 1                       0.76
  yes                          132        0.89 (0.42--1.88)                           
  adjuvant radiation therapy   no         105                 1                       0.29
  yes                          210        0.71 (0.31--1.35)                           
  TOP2A overexpression         no         136                 1                       0.002
  yes                          179        4.00 (1.65--9.54)                           

Abbreviations: PgR; progesteron receptor.

Prognostic value of *TOP2A* amplified in HER2 positive breast cancer {#s2_3}
--------------------------------------------------------------------

Because *TOP2A* amplified was strongly associated with HER2 positivity, the prognostic value of *TOP2A* amplified was examined using the log-rank test in HER2 positive breast cancer. In 135 patients with HER2 positive breast cancer, the rates of administration of adjuvant anthracycline, taxane, and trastuzumab were 56.7%, 64.1%, and 76.1, respectively. *TOP2A* amplified was associated with better relapse-free survival (5-year RFS; *TOP2A* amplified vs. normal/deleted, 96.2% vs. 83.8%, *p* = 0.043, log-rank test, Figure [2A](#F2){ref-type="fig"}). Cox regression analysis, which included other prognostic factors, confirmed a trend that indicated better prognoses in patients with *TOP2A* amplified (HR 0.30, 95% CI 0.085--1.07, *p* = 0.063). As exploratory analysis, the prognostic value of adjuvant anthracycline therapy was examined with respect to the presence of *TOP2A* amplified; however, adjuvant anthracycline therapy was not associated with survival advantages for patients with or without *TOP2A* amplified (Figure [2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}).

![Prognostic value of *TOP2A* amplified and adjuvant anthracycline therapy in HER2 positive breast cancer\
(**A**) Relapse-free survival of the whole population (*n* = 135), and the (**B**) *TOP2A* amplified (*n* = 57), and (**C**) *TOP2A* normal/deleted (*n* = 78) populations, stratified by adjuvant anthracycline treatment. *P* value was evaluated using the log-rank test.](oncotarget-09-26701-g002){#F2}

DISCUSSION {#s3}
==========

The treatment strategy for breast cancer has dramatically changed following the introduction of tailored therapy based on breast cancer subtypes \[[@R15]\]. Tailored therapy utilizing endocrine therapy, chemotherapy, and HER2-targeting therapy has significantly improved the prognoses of early and advanced breast cancers \[[@R16]--[@R20]\]. The diagnosis of breast cancer subtype was initially developed based on gene-expression signature \[[@R21]\]; however, the hormone receptor expression, HER2 status, and proliferation markers were clinically replaced by multi-gene assay in the analyses \[[@R15]\]. Luminal breast cancer, defined as hormone receptor-positive and HER2 negative breast cancer, is clinically divided into luminal A and luminal B breast cancer using PgR and Ki67 index \[[@R22], [@R23]\]. Luminal A breast cancer defined as ER and PgR positive with a low Ki67 index has been proven to have an excellent prognosis \[[@R24], [@R25]\]. In this study, the prognosis of luminal A breast cancer was also excellent, as indicated by the 5-year RFS of 97.6%. Compared with luminal A breast cancer, luminal B breast cancer has significant risks of recurrence, and it has been examined for further risk assessment to refine the adaptation of adjuvant chemotherapy. While multi-gene assays can detect low- or high-risk populations of patients with luminal breast cancers, the value of chemotherapy in the intermediate-risk population is still inconclusive \[[@R26], [@R27]\]. Additionally, multi-gene assays cannot be performed in individual institutions, and the high cost may prevent these assays from becoming comprehensive. Patient management would benefit from additional and convenient prognostic markers in adjuvant luminal B breast cancer.

TOP2A is a representative proliferation marker, and previous reports have shown that high TOP2A expression was associated with poor prognosis in hormone receptor-positive breast cancer \[[@R7], [@R9], [@R28]\]. In our study, we also used IHC analysis to evaluate TOP2A overexpression as a significant prognostic factor in luminal breast cancer; however, the prognostic value was restricted in luminal B breast cancer, defined as tumors with high Ki67 index and/or low PgR expression. This result is different from a previous report in which the prognostic effect of TOP2A gene expression was independent of Ki67 expression in ER positive tumors \[[@R8]\]. A conservative median split of *Ki67* gene expression in that study may have led to different prevalence of luminal breast cancer subtype in our study. In this study, luminal breast cancer was subtyped using PgR and Ki67 index of established cut-off values, 20% and 14%, respectively \[[@R22], [@R29]\]. Our findings supported a previous report of a pooled analysis of four independent gene expression data sets evaluating the prognostic value of TOP2A RNA expression in luminal breast cancer \[[@R30]\]. In that study, the prognostic value of *TOP2A* expression was evaluated in a population at intermediate-risk for simulated Oncotype DX recurrence sore using proliferation marker components. The authors concluded that *TOP2A* expression is also useful for identifying those with an intermediate recurrence score who are more likely to relapse. Although TOP2A overexpression was associated with a higher Ki67 index, as shown in previous report \[[@R31]\], TOP2A overexpression remained a significant prognostic factor after adjusting for other clinicopathological factors, including Ki67 index. This result suggests that evaluating the proliferation markers of TOP2A and Ki67 has clinical significance in predicting the risk of relapse in luminal breast cancer. The analysis of TOP2A overexpression by IHC may be superior to the analysis of gene expression with respect to the universality and the convenience. In this study, the cut-off value of TOP2A overexpression was determined as 10%, in accordance with the results of previous studies. In an exploratory analysis, the ROC curve indicated an optimal TOP2A expression cutoff value of 11.5% for predicting 5-year RFS in luminal B breast cancer, which is approximate to 10% of TOP2A expression adopted in this study. Considering the comprehensiveness and the reproducibility of the results of previous studies, 10% of TOP2A expression can be a reasonable cut-off value for predicting recurrence in luminal B breast cancer.

TOP2A is known as a molecular target of anthracycline, and previous meta-analysis has shown that *TOP2A* amplified was predictive marker for anthracycline-based chemotherapy regimens \[[@R11]\]. A meta-analysis of adjuvant randomized trials comparing anthracycline-based treatment with CMF suggested that *TOP2A* amplified predicted responsiveness to anthracycline-based chemotherapy in patients with early breast cancer. Patients with *TOP2A* amplified tumor had higher risk reductions for relapse and survival compared with normal *TOP2A* tumor by anthracycline-containing chemotherapy. In this study, the prognostic value of *TOP2A* amplified was evaluated in HER2 positive breast cancer because *TOP2A* amplified was shown to be strongly associated with HER2 positivity, as shown in previous studies \[[@R13], [@R28]\]. Unlike above mentioned report, our study failed to show the advantage of anthracycline therapy in patients with *TOP2A* amplified and HER2 positive breast cancer. Several reasons may account for this discrepancy. First, *TOP2A* amplified did not affect the prognosis of HER2 positive breast cancer treated with standard adjuvant treatment of trastuzumab-containing chemotherapy \[[@R32], [@R33]\]. In a single arm study of adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified breast cancer, patients with or without *TOP2A* amplified had excellent prognoses (3-year DFS; *TOP2A* amplified vs. normal/deleted, 97.2% vs. 96.4%) \[[@R33]\]. In BCIRG-006, HER2 positive breast cancer was treated with anthracycline, taxane, plus trastuzumab showed equivalent prognoses, irrespective of *TOP2A* status (5-year DFS; *TOP2A* amplified vs. normal/deleted, 85% vs. 83%) \[[@R32]\]. Second, previous reports showing the predictive value of *TOP2A* amplified compared anthracycline-based chemotherapy regimens with CMF \[[@R11]\], which is no longer used as a standard treatment regimen for HER2 positive breast cancer. Recent clinical trials have shown excellent prognosis of HER2 positive early breast cancer treated with non-anthracycline regimens consisting of taxane and trastuzumab \[[@R33], [@R34]\]. Considering the excellent prognosis of HER2-positive breast cancer, to facilitate the decision of adjuvant anthracycline therapy based on the evaluation of *TOP2A* amplified may lack clinical meaning.

This study has some limitations. First, this retrospective analysis from a single institution could have biases and a multiple-institutional prospective study is needed to confirm our results. Second, PgR expression and Ki67 index were substituted for a multigene expression classifier, such as Oncotype Dx or Mammaprint, to distinguish luminal B from luminal A breast cancer in this study. Some discrepancies between the multi-gene assay and analysis of conventional pathological markers in determining intrinsic subtype may exist. Third, a small number of cases and events in HER2 positive breast cancer is underpowered to make conclusion about the predictive value of *TOP2A* amplified in anthracycline treatment.

In conclusion, our study indicates that TOP2A overexpression is a marker for poor prognosis, especially in cases of luminal B breast cancer. In contrast, the *TOP2A* amplified is limited in HER2 positive breast cancer, and the presence of the *TOP2A* amplified does not influence the survival advantage of adjuvant anthracycline therapy. To tailor the adjuvant therapy based on breast cancer subtype, the assessment of TOP2A overexpression may be considered for risk assessment in luminal B breast cancer.

MATERIALS AND METHODS {#s4}
=====================

Patients and methods {#s4_1}
--------------------

Between May 2005 and Apr 2015, a total of 643 consecutive non-metastatic invasive breast cancers were evaluated at the Kure Medical Center and the Chugoku Cancer Center, Kure, Japan, for their TOP2A status using IHC to analyze TOP2A overexpression and FISH analysis for *TOP2A* amplified. The prognostic value of TOP2A status was retrospectively evaluated in this study. The Kure Medical Center review board approved this study (29--23). The requirement for informed consents from individual patients was waived because this was a retrospective review of a prospectively maintained patient database.

Clinicopathological factors {#s4_2}
---------------------------

The clinicopathological factors in this study, derived from a prospectively maintained database at our institute, included patient age, histological type of cancer, prescribed neoadjuvant therapy, T and N stage according to the TNM classification, nuclear grade, estrogen receptor (ER) status, progesterone receptor (PgR) status, human epidermal growth factor receptor 2 (HER2) status, Ki67 index, breast cancer subtype, prescription of anthracycline and taxane, and recurrence (Table [1](#T1){ref-type="table"}). ER and PgR status were determined using IHC assays, and tumors with 1% or more of positively-stained tumor cells were classified as positive for ER and PgR. The HER2 status was determined using IHC and FISH individually or in combination. HER2 positive tumors were defined as those with an IHC score of 3+ or those showing HER2 gene amplification using FISH, in accordance with the ASCO guidelines \[[@R35]\]. Breast cancer subtypes were determined using surrogate markers, including ER, PgR, HER2, and Ki67 index, as described below \[[@R15], [@R22], [@R23]\];

-   Luminal A: ER positive, HER2 negative, Ki67 \<14%, and PgR positive ≥20%

-   Luminal B: ER positive, HER2 negative, and Ki67 ≥14%, or PgR positive \<20%

-   HER2: HER2 positive, and any one of the following: ER, PgR and Ki67

-   Triple negative breast cancer (TNBC): ER, PgR, and HER2 negative

Adjuvant therapy was essentially determined in accordance with clinical guidelines. Patients with luminal A or B breast cancers were administered adjuvant endocrine therapy for 5 years. The determination of adjuvant chemotherapy for luminal type breast cancer was based on breast cancer recurrence risks and the preference of the patients. One-year adjuvant trastuzumab therapy was administered in cases of HER2 positive breast cancer. Patients with TNBC received adjuvant chemotherapy. Adjuvant chemotherapy essentially consisted of anthracycline- and taxane-based regimens administered individually or in combination. Postoperative follow-up was performed in accordance with the guidelines for medical checks and annual mammography. In cases with signs of recurrence, image tests and biopsies were performed to confirm the status. Recurrence-free survival (RFS) was defined as the elapsed time from the date of surgery until the date of the first event (relapse or death from any cause) or of last follow-up.

Evaluation of TOP2A overexpression and *TOP2A* amplified in this study {#s4_3}
----------------------------------------------------------------------

TOP2A overexpression was analyzed by IHC \[[@R12]\]. Briefly, 4-μm-thick paraffin sections were prepared, and the formalin-fixed and paraffin-embedded tumor tissues were stained with monoclonal TOP2A antibodies (Ki-S1, Dako). IHC staining was performed using auto-stainers (Ventana), and the results were stored digitally after examination by virtual microscopy (Hamamatsu Photonics). Only nuclear staining was considered for determining TOP2A positivity. Immunostaining frequency of the tumor cells was automatically evaluated using Genie/Aperio software. Tumors with definitive TOP2A staining in more than 10% of the tumor cells were considered as TOP2A overexpression, in accordance with previous reports \[[@R9], [@R36]\]. The intensity score of staining was not considered in this analysis. Representative microscopic findings of nuclear staining for TOP2A overexpression and normal breast cancer, and auto-analysis of frequency of TOP2A positive cells are shown in ([Supplementary Figure 1A, 1B](#SD1){ref-type="supplementary-material"}). *TOP2A* amplified was evaluated using FISH analysis, as described previously \[[@R37]\]. Briefly, a dual-color probe containing a spectrum orange-labeled *TOP2A* gene and a spectrum green-labeled centromere control for chromosome 17 were evaluated (DAKO). FISH ratios of 2 or higher, 0.8 to 1.9, and \<0.8 were designated as *TOP2A* amplified, normal, and deleted, respectively. Representative microscopic findings of *TOP2A/CEP17* for *TOP2A* amplified and normal breast cancer are shown in ([Supplementary Figure 2A, 2B](#SD1){ref-type="supplementary-material"}). The clinical values of TOP2A overexpression and *TOP2A* amplified were evaluated in accordance with REMARK criteria \[[@R38]\].

Statistical analysis {#s4_4}
--------------------

The association between the clinicopathological factors and TOP2A status was assessed using the χ^2^ test. Kaplan--Meier survival curves and the log rank test were used to determine the univariate significance of the variables. A Cox regression model was used to examine multiple covariates for survival. Statistical analyses were carried out using SPSS software (version 11 for Windows; 5 SAS Institute, Tokyo, Japan). A *p*-value of \< 0.05 was considered as statistically significant.

SUPPLEMENTARY MATERIALS AND FIGURES {#s5}
===================================
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